Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The report was just about

It appears that TPL has manipulated things so that PTSC will never be in a position to contribute more money than required to the working capital fund of PDS, thereby eliminating any chance of PTSC getting a larger % of PDS.

Doesn't it seem easy enough for TPL to submit expenses for reimbursement that are large enough to offset the required capital contribution and/or ask PTSC for loan. I doubt that Leckrone would ever let PTSC gain control of PDS?

Again, I am not an accountant and corrections are welcome.

Share
New Message
Please login to post a reply